Longboard Pharmaceuticals

Channeling innovation to change the course of rare neurological diseases

Welcome to Longboard Pharmaceuticals, a clinical-stage company leveraging over 20 years of proven GPCR discovery research to develop first- or best-in-class therapies with optimized pharmacology and pharmacokinetics to transform the lives of patients living with rare neurological diseases.

About

Longboard Pharmaceuticals is a team driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases.

Longboard’s proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.  

Longboard, formerly known as Arena Neuroscience, was a wholly-owned subsidiary of Arena Pharmaceuticals, Inc. until its launch in October 2020.  Longboard’s compounds were discovered and evolved out of Arena’s validated world-class GPCR research engine.

Management

Kevin Lind

President and CEO

Phil Perera, MD

Chief Medical Officer

Chad Orevillo

Vice President and Head of Operations

Investors

Longboard’s investor syndicate includes Farallon Capital, Cormorant Asset Management, HBM Healthcare Investments, Highside Capital Management, and T. Rowe Price Associates, with participation from Arena Pharmaceuticals.

arena
farallon
cormorant
hbm
highside
troweprice

Pipeline

ProgramMechanism of ActionTherapeutic AreaDrug DiscoveryIND-EnablingEarly Clinical
LP352 Potentially most potent, selective 5-HT2C agonist Developmental and Epileptic Encephalopathies (DEEs) Refractory Focal Epilepsies

LP143 CB2 receptor agonist ALS, PD

LP659 S1P receptor modulator Multiple CNS neuroinflammatory disorders

Undisclosed - -

DrugMOAStage
LP352 Potentially most potent, selective 5-HT2C agonist Early Clinical
LP143 CB2 receptor agonist IND-Enabling
LP659 S1P receptor modulator IND-Enabling
Undisclosed -IND-Enabling

Careers

WE ARE COMMITTED TO IMPROVING LIVES.

WE STRIVE TO BE THE BEST POSSIBLE TEAMMATES AND COLLEAGUES.

WE ARE LOOKING FOR PEOPLE TO JOIN OUR TEAM WHO ARE JUST AS DYNAMIC, TALENTED, AND PASSIONATE AS WE ARE.

We are an equal-opportunity employer offering competitive benefits. Our open positions are listed below. To apply, please send your CV to [email protected] with the position you are applying for in the subject line.

If the position you are looking for is not listed, please check back frequently for new open positions, as our team is growing rapidly.

Contact

6154 Nancy Ridge Drive, San Diego, CA 92121
(619) 592-9775 | [email protected]